The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease
Open accessAbstract
BACKGROUND: Reverse-transcriptase inhibitors have only moderate clinical efficacy against the human immunodeficiency virus type 1 (HIV-1). Ritonavir is an inhibitor of HIV-1 protease with potent in vitro anti-HIV properties and good oral bioavailability. METHODS: We evaluated the antiviral activity and safety of ritonavir in a double-blind, randomized, placebo-controlled phase 1 and 2 study of 84 HIV-positive patients with 50 or more CD4+ lymphocytes per cubic millimeter. The patients were randomly assigned to one of four regimens of ritonavir therapy, or to placebo for four weeks and then (by random assignment) to one of the ritonavir regimens. RESULTS: During the first 4 weeks, increases in CD4+ lymphocyte counts and reductions in the log number of copies of HIV-1 RNA per milliliter of plasma were similar among the four dosage groups, but in the three lower-dosage groups there was a return to base-line levels by 16 weeks. After 32 weeks, in the seven patients in the highest-dosage group (600 mg of ritonavir every 12 hours), the median increase from base line in the CD4+ lymphocyte count was 230 cells per cubic millimeter, and the mean decrease in the plasma concentration of HIV-1 RNA (as measured by a branched-DNA assay) was 0.81 log (95 percent confidence interval, 0.40 to 1.22). In a subgroup of 17 patients in the two higher-dosage groups, RNA was also measured with an assay based on the polymerase chain reaction, and after eight weeks of treatment there was a mean maximal decrease in viral RNA of 1.94 log (95 percent confidence interval, 1.37 to 2.51). Adverse events included nausea, circumoral paresthesia, elevated hepatic aminotransferase levels, and elevated triglyceride levels. Ten withdrawals from the study were judged to be related to ritonavir treatment. CONCLUSIONS: In this short-term study, ritonavir was well tolerated and had potent activity against HIV-1, but its clinical benefits remain to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
Self-citationViral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Active human immunodeficiency virus protease is required for viral infectivity
Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., Scolnick, E. M., & Sigal, I. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4686 · Cited by 1,307
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., et al. (1995) · Nature · doi:10.1038/374569a0 · Cited by 974
Kempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., & Kong, X. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2484 · Cited by 560
Mulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L., & Kwok, S. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.2.292-300.1994 · Cited by 558
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Self-citationThe HIV-1 Protease as a Therapeutic Target for AIDS
DEBOUCK, C. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.153 · Cited by 341
Havlir, D., Cheeseman, S. H., Mclaughlin, M., Murphy, R., Erice, A., Spector, S. A., Greenough, T. C., Sullivan, J. L., Hall, D., Myers, M., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.3.537 · Cited by 298
Pachl, C. A., Todd, J. A., Kern, D. G., Sheridan, P. J., Fong, S.-J., Stempien, M. M., Hoo, B., Besemer, D. J., Yeghiazarian, T., Irvine, B. D., et al. (1995) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199504120-00003 · Cited by 232
Cited by
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Self-citationFlexner, C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381808 · Cited by 852
Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., Glesby, M. J., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378131 · Cited by 580
Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.654 · Cited by 417
Self-citationAdherence to Antiretroviral and Pneumocystis Prophylaxis in HIV Disease
Eldred, L. J., Wu, A. W., Chaisson, R. E., & Moore, R. D. (1998) · Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · doi:10.1097/00042560-199806010-00003 · Cited by 273
Metadata
- Authors
- Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., Aguado, A. G., Garcia de Lomas, J., Delgado, R., Borleffs, J. C. C., Hsu, A., Valdes, J. M., Boucher, C. A. B., & Cooper, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-12-07
- Volume
- 333
- Issue
- 23
- Pages
- 1528-1534
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2339057709
- Cited by
- 567
- References
- 13
- FWCI
- 54.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease. https://app.cochat.ai/papers/10.1056/nejm199512073332303
- The paper
- Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., Aguado, A. G., Garcia de Lomas, J., Delgado, R., Borleffs, J. C. C., Hsu, A., Valdes, J. M., Boucher, C. A. B., & Cooper, D. A. (1995). A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease. New England Journal of Medicine. https://doi.org/10.1056/nejm199512073332303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
